# To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

> **NCT03220217** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 29 (actual)

## Conditions studied

- Gastro-Enteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Satoreotide trizoxetan 5-20μg
- **DRUG:** Satoreotide trizoxetan 30-45μg

## Key facts

- **NCT ID:** NCT03220217
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-08-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220217, "To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03220217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*